Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Pieternella J. Lugtenburg, Martine E.D. Chamuleau et al.|The Lancet|2021

Cited by 337